Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients

Otsuka

Status and phase: Completed; Phase 2

Conditions: Congestive Heart Failure

Treatments: Drug: Tolvaptan

Study type: Interventional

Funder types: Industry

Identifiers

NCT00043771

156-01-231

Details and patient eligibility

About

Patients with congestive heart failure will be assessed for safety and clinical effects of Tolvaptan 30 mg every day versus 15 mg twice a day over a period of 7 days.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

History of CHF

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind